Skip to main content
CNS Neuroscience & Therapeutics logoLink to CNS Neuroscience & Therapeutics
. 2022 Jun 25;28(8):1274. doi: 10.1111/cns.13900

Corrigendum

PMCID: PMC9253734  PMID: 35751852

In Zhang et al., 1 the authors noticed that the same figure was accidently presented in Figure 1K and L.

FIGURE 1.

FIGURE 1

GFAP, IL‐1β, IL‐6, and TNF‐α in serial sections of sural nerve. The brown inclusions inside the nerve bundles were positive immunoreaction to GFAP (A, E, I), IL‐1β (B, F, J), IL‐6(C, G, K), and TNF‐α (D, H, L) in a 60‐y‐old female PD patient with sensory disturbances (A–D) (case PD patient 11 in Table 1), a 71‐year‐old female PD patient without sensory disturbances (E–H) (case PD patient 10 in Table 1) and a 63‐year‐old male control without neuropathy (I–L) (case Control 1 in Table 1). Original magnification was 100×. Insets were all set at magnification (400×). Abbreviations: GFAP, glial fibrillary acid protein; HC, healthy controls; IL‐1β, interleukin‐1‐beta; IL‐6, interleukin‐6; PD, Parkinson's disease; PDS (−), PD patient without sensory disturbances; PDS (+), PD patient with sensory disturbances; TNF‐α, tumor necrosis factor‐alpha

The correct Figure 1 is given below:

The Author's apologize for this error.

REFERENCE

  • 1. Zhang H, Wu J, Shen F‐F, et al. Activated Schwann cells and increased inflammatory cytokines IL‐1β, IL‐6, and TNF‐α in patients' sural nerve are lack of tight relationship with specific sensory disturbances in Parkinson's disease. CNS Neurosci Ther. 2019;26:518‐526. doi: 10.1111/cns.13282 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CNS Neuroscience & Therapeutics are provided here courtesy of Wiley

RESOURCES